Pharmacodynamic study of sunitinib malate in patients with renal cell cancer and other advanced solid malignancies.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer; Renal cell carcinoma; Solid tumours
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 15 May 2013 Planned end date changed from 1 Mar 2008 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
- 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.